
Daniel James Delitto MD PhD
Surgical Oncology (Other than Breast)
Surgical Oncologist, Hepatobiliary Surgeon and Assistant Professor, Department of Surgery
Join to view full profile
300 Pasteur DrPalo Alto, CA 94304
Phone+1 650-723-4000
Dr. Delitto is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Delitto is a fellowship-trained surgical oncologist with a focus on conditions of the liver, pancreas, and stomach. He is an assistant professor in Stanford Medicine’s Department of Surgery.
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.
Education & Training
Johns Hopkins University School of MedicineFellowship, Complex General Surgical Oncology, 2019 - 2021
University of FloridaResidency, Surgery, 2011 - 2019
University of Florida College of MedicinePhD, Immunology, 2013 - 2016
University of Pittsburgh School of MedicineClass of 2011
Certifications & Licensure
CA State Medical License 2021 - 2027
MD State Medical License 2019 - 2022
American Board of Surgery Surgery
American Board of Surgery Complex General Surgical Oncology
Publications & Presentations
PubMed
- 2 citationsBiochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?Mohammed Usman Ahmad, Christopher S Javadi, Julia D Chang, Erna Forgó, Daniel J Delitto
Annals of Surgery. 2026-08-01 - Protocol to interrogate the role of creeping fat and mechanical tension in Crohn's disease using a surgical mouse model of intestinal fibrosis.Elijah J Suh, Benjamin Pham, Khristian E Bauer-Rowe, Alexia Kim, Norah E Liang
STAR Protocols. 2026-06-19 - Hepatocellular Carcinoma: A Practical Anatomy-Based Guide for Staging and Treatment Planning, From theSpecial Series on Critical Anatomy.Sung-Hua Chiu, Andrew Kesselman, Daniel Delitto, Renumathy Dhanasekaran, Wei-Chou Chang
AJR. American Journal of Roentgenology. 2026-06-01
Press Mentions
Early-Career Physician-Scientists Receive Major Support from Damon Runyon Cancer Research FoundationJuly 13th, 2025
A Pancreatic Cancer Drug Provides New Hope: Five Things to Know About DaraxonrasibJune 25th, 2026
Grant Support
- Reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic adenocarcinomaSTANFORD UNIVERSITY2026–2031
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









